Adding abiraterone to ADT and docetaxel improves survival in metastatic prostate cancer
Adding abiraterone to standard treatment provides a lasting survival benefit for men whose prostate cancer has already spread at diagnosis, reinforcing the value of early treatment intensification. The findings come from ...
Oct 26, 2026
0
7






